genuine question about API source that I am slightly embarrassed to ask
Question in the title, detail here: genuine question about API source that I am slightly embarrassed to ask.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
if a clinic will not name the facility, that is your answer
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
[removed by moderator]
ask which facility, then ask for their testing
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
the API source is the question nobody asks and everybody should
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Who is the prescriber, and are they the same organisation as the pharmacy?
salt forms are the recurring argument and the answer is boring
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
the price difference is mostly the intake, not the vial
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
compounded is not generic, there is no equivalence claim
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
the label on a compounded vial is a legal document, read it
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
the shortage list is the whole legal hinge and people skip it
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
- 1Same view. If the intake asked you nothing, the intake was a formality and…8 comments in this branch · started by u/camila_sandvik
- 2This. Compounded preparations carry no equivalence claim, and treating them…8 comments in this branch · started by u/hassan_chowdhury